BF Biosciences Statistics
Total Valuation
BF Biosciences has a market cap or net worth of PKR 13.65 billion. The enterprise value is 14.06 billion.
Market Cap | 13.65B |
Enterprise Value | 14.06B |
Important Dates
The next estimated earnings date is Thursday, May 29, 2025.
Earnings Date | May 29, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
BF Biosciences has 88.33 million shares outstanding. The number of shares has increased by 8.15% in one year.
Current Share Class | 88.33M |
Shares Outstanding | 88.33M |
Shares Change (YoY) | +8.15% |
Shares Change (QoQ) | +16.66% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | 1.59% |
Float | 25.00M |
Valuation Ratios
The trailing PE ratio is 29.47 and the forward PE ratio is 18.84.
PE Ratio | 29.47 |
Forward PE | 18.84 |
PS Ratio | 2.75 |
PB Ratio | 3.01 |
P/TBV Ratio | 3.01 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.67, with an EV/FCF ratio of -37.71.
EV / Earnings | 35.89 |
EV / Sales | 2.84 |
EV / EBITDA | 15.67 |
EV / EBIT | 18.56 |
EV / FCF | -37.71 |
Financial Position
The company has a current ratio of 2.42, with a Debt / Equity ratio of 0.41.
Current Ratio | 2.42 |
Quick Ratio | 1.11 |
Debt / Equity | 0.41 |
Debt / EBITDA | 2.06 |
Debt / FCF | -4.96 |
Interest Coverage | 77.36 |
Financial Efficiency
Return on equity (ROE) is 11.48% and return on invested capital (ROIC) is 8.71%.
Return on Equity (ROE) | 11.48% |
Return on Assets (ROA) | 6.74% |
Return on Invested Capital (ROIC) | 8.71% |
Return on Capital Employed (ROCE) | 11.56% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.71 |
Inventory Turnover | 2.19 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | 158.94 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 52.12 |
Average Volume (20 Days) | 1,134,516 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BF Biosciences had revenue of PKR 4.96 billion and earned 391.70 million in profits. Earnings per share was 5.24.
Revenue | 4.96B |
Gross Profit | 2.00B |
Operating Income | 757.55M |
Pretax Income | 619.99M |
Net Income | 391.70M |
EBITDA | 896.83M |
EBIT | 757.55M |
Earnings Per Share (EPS) | 5.24 |
Balance Sheet
The company has 1.44 billion in cash and 1.85 billion in debt, giving a net cash position of -411.99 million or -4.66 per share.
Cash & Cash Equivalents | 1.44B |
Total Debt | 1.85B |
Net Cash | -411.99M |
Net Cash Per Share | -4.66 |
Equity (Book Value) | 4.54B |
Book Value Per Share | 57.91 |
Working Capital | 2.30B |
Cash Flow
In the last 12 months, operating cash flow was -137.11 million and capital expenditures -235.70 million, giving a free cash flow of -372.82 million.
Operating Cash Flow | -137.11M |
Capital Expenditures | -235.70M |
Free Cash Flow | -372.82M |
FCF Per Share | -4.22 |
Margins
Gross margin is 40.44%, with operating and profit margins of 15.28% and 7.90%.
Gross Margin | 40.44% |
Operating Margin | 15.28% |
Pretax Margin | 12.51% |
Profit Margin | 7.90% |
EBITDA Margin | 18.09% |
EBIT Margin | 15.28% |
FCF Margin | n/a |
Dividends & Yields
BF Biosciences does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -8.15% |
Shareholder Yield | -8.15% |
Earnings Yield | 2.87% |
FCF Yield | -2.73% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |